for females ages 18 years and up (full criteria)
at Santa Barbara, California and other locations
study started



This is a randomized, double-blind, placebo-controlled, multicenter, pre-operative Phase II study designed to estimate the efficacy of ipatasertib combined with paclitaxel chemotherapy versus placebo combined with paclitaxel chemotherapy in women with Stage Ia - IIIa triple-negative breast adenocarcinoma. The anticipated time on study treatment is 12 weeks.

Official Title

A Phase II Randomized, Double-Blind, Study of Ipatasertib (GDC-0068), an Inhibitor to AKT, in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer


Breast Cancer Breast Neoplasms Triple Negative Breast Neoplasms Paclitaxel Albumin-Bound Paclitaxel Ipatasertib Ipatasertib + Paclitaxel


You can join if…

Open to females ages 18 years and up

  • Premenopausal or postmenopausal women
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Histologically documented, Stage Ia to operable Stage IIIa, triple-negative carcinoma of the breast with primary tumor greter than or equal to (>/=) 1.5 centimeters (cm) in largest diameter (cT1-3) by MRI
  • Adequate hematologic and organ function within 14 days before the first study treatment
  • Availability of tumor tissue from formalin-fixed, paraffin-embedded (FFPE) core biopsy of breast primary tumor
  • For female participants of childbearing potential, agreement to use highly effective form(s) of contraception for the duration of the study and for at least 6 months after last dose of study treatment

You CAN'T join if...

  • Known human epidermal growth factor 2 (HER2)-positive, estrogen receptor (ER)-positive, or progesterone receptor (PgR)-positive breast cancer
  • Any prior treatment for the current primary invasive breast cancer
  • Participants with cT4 or cN3 stage breast tumors
  • Metastatic (Stage IV) breast cancer
  • Bilateral invasive breast cancer
  • Multicentric breast cancer
  • Any disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk from treatment complications


  • Sansum Medical Clinic, Inc.
    Santa Barbara California 93105 United States
  • Northwest Cancer Specialists - Portland (NE Hoyt St)
    Portland Oregon 97213 United States


accepting new patients
Start Date
Completion Date
Genentech, Inc.
Sign up for this study
Phase 2
Study Type
Last Updated